ArticleHemaSphere2026
Immunophenotypic abnormality quantification refines multiparameter flow cytometry-based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Impact of Induction With Azacitidine and Venetoclax Versus Intensive Chemotherapy on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia.Journal of hematology · 2026Article
- Significance of CD34Transplantation and cellular therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Flow cytometry-based measurable residual disease (MRD) testing is routinely used in acute myeloid leukemia (AML), but methodologies need refinement to optimize assay characteristics. Here, we examined 1215 adults with AML or myelodysplastic syndrome/AML allografted in morphologic remission to study how the type(s) of leukemic blasts and degree/number of immunophenotypic abnormalities could improve MRD testing. Among 233 patients with pre-hematopoietic cell transplantation (pre-HCT) MRD, 80 (34%) had non-stem cell-like (NSC-like) leukemic blasts, 109 (47%) had stem cell-like (SC-like) leukemic blasts, and 44 (19%) had NSC- and SC-like leukemic blast cell populations. Across all MRD
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.